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Summary. Fluoroquinolone treatment failure has been reported in patients with nalidixic acid-resistant Salmonella infec-
tions. Both chromosomal- and plasmid-mediated quinolone-resistance mechanisms have been described. The objective of this
study was to identify the prevalence of these mechanisms in a collection of 41 Salmonella spp. clinical isolates causing acute
gastroenteritis, obtained in the Hospital Clinic, Barcelona. The minimum inhibitory concentrations (MICs) of nalidixic acid
and ciprofloxacin were determined by Etest. Mutations in the quinolone-resistance determining regions (QRDRs) of the gyrA,
gyrB, and parC genes and the presence of the qnr, aac(6′)-Ib-cr, and qepA genes were detected by PCR and DNA sequenc-
ing. All isolates showed constitutive expression of an efflux pump. None of the isolates were ciprofloxacin-resistant, whereas
41.5% showed nalidixic acid resistance associated with a mutation in gyrA and overexpression of an efflux pump. Although
qnrS1, qnrB6, and qepA were found in four isolates, the expression of these genes was not associated with decreased
quinolone susceptibility. Mutations in the gyrA gene and overexpression of an efflux pump were critical for nalidixic acid
resistance and decreased susceptibility to ciprofloxacin in these isolates. However, plasmid-mediated quinolone resistance did
not seem to play a major role. To our knowledge, this is the first description of qepA in Salmonella. [Int Microbiol 2010;
13(1):15-20]
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Introduction
Non-typhoidal Salmonella isolates typically cause a self-lim-
iting gastroenteritis, leading to bacteremia in 1–4% of cases.
Bacteremia can result in complications, such as osteo-
myelitis, visceral abscesses, and endocarditis. These compli-
cations occur more frequently in the elderly and immunosup-
pressed [14]. Furthermore, Salmonella infection is often
more serious in the developing world, where the levels of
antibiotic resistance are higher [2,21].
Antimicrobial therapy is rarely necessary for Salmonella
infection, but in cases of systemic salmonellosis, fluoro-
quinolones are used for treatment in adults, and third-gener-
ation cephalosporins for treatment in children [20]. Since its
introduction, nalidixic acid resistance has steadily increased
in Salmonella. However, despite wide use of fluoro-
quinolones such as ciprofloxacin, the levels of resistance to
these antimicrobials remain low [15]. Resistance to
quinolones is mainly due to: (i) mutations in the quinolone-
resistance determining regions (QRDRs) of the target genes
(gyrA and gyrB, which encode DNA gyrase, and parC and
parE, which encode topoisomerase IV), and (ii) low accumu-
lation of the antimicrobial within the cell, mostly associated
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with increased efflux due to overexpression of the AcrAB-
TolC efflux pump [9]. Plasmid-mediated quinolone resist-
ance is also emerging: qnr, qepA and aac(6′)-Ib-cr are plas-
mid-encoded genes that confer quinolone resistance. Qnr com-
prises a group of pentapeptide repeat proteins that protect bac-
teria against quinolones in a dose-dependent manner [22].
QepA is a plasmid-encoded efflux pump that significantly
affects susceptibility to norfloxacin [23], and Aac(6′)-Ib-cr is a
modified aminoglycoside N-acetyltransferase [18] that acety-
lates some fluoroquinolones, including ciprofloxacin.
The aim of this study was to understand the role of the
different mechanisms of quinolone resistance that generate
decreased susceptibility to quinolones among a collection of
Salmonella spp. clinical isolates.
Materials and methods
Bacteria. Bacterial clinical isolates were obtained from Salmonella-
Shigella agar plates (BD) inoculated with stool samples of patients with
acute gastroenteritis during the period July 2007–October 2008 in the
Department of Clinical Microbiology, Hospital Clinic, Barcelona, Spain.
There were 41 isolates of Salmonella enterica: 19 S. Typhimurium; 19 S.
Enteritidis; 1 S. Hadar; 1 S. Muenchen and 1 S. Choleraesuis. Specific anti-
sera were used for typing the serovar. 
Susceptibility testing. Antimicrobial susceptibility testing was per-
formed using Etests (AB Biodisk, Solna, Sweden) on Mueller Hinton plates
(Oxoid) following the manufacturer’s recommendations. When the suscepti-
bility of the isolates was too high to be measured by Etest, the MICs of those iso-
lates were determined by the broth microdilution method according to the
Clinical and Laboratory Standards Institute (CLSI, formerly National Com-
mittee for Clinical Laboratory Standards, NCCLS) [7] and as described in [8].
Detection of target gene mutations and presence of plas-
mid-encoded determinants. PCR was carried out to screen for
mutations in the QRDRs of the gyrA, gyrB, and parC genes, and for the pres-
ence of qnr, qepA, and aac(6′)-Ib-cr. Bands of the correct size were excised
and purified using the Wizard SV Gel and PCR Clean-Up System kit
(Promega, Madison, WI, USA), then quantified using a GeneQuest spec-
trophotometer (Cecil CE2302) and sent to Macrogen (Seoul, Korea) for
sequencing. The results were analyzed using BLAST (PubMed) or by direct
comparison with the gene sequences for the appropriate serotype. The
primers used for PCR amplification and sequencing are listed in Table 1. 
Statistical analysis. SPSS 15.0 for Windows was used for statistical
analysis. Normality was assessed using histograms. Chi-square tests were
done for comparisons of proportions. The Wilcoxon matched pairs test was
applied for analysis of paired subjects when differences were not normal.
Results
Antimicrobial susceptibility testing revealed that all isolates
were susceptible to ciprofloxacin (MICs: 0.012–0.75 μg/ml),
whereas 41.5% of Salmonella isolates were nalidixic acid-
resistant (MICs: 64–512 μg/ml). Of the 19 isolates of S. Ente-
ritidis, 16 were resistant to nalidixic acid, whereas all 19 S. Ty-
phimurium isolates were susceptible. Among the remaining
three species, only S. Hadar was resistant to nalidixic acid.
The results are shown in Table 2.
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Table 1. List of primers used in this study
Gene Primer (5′ to 3′) Temperature (°C) Reference
gyrA AAATCTGCCCGTGTCGTTGGT 58 [8]
GCCATACCTACTGCGATACC
gyrB GAATACCTGCTGGAAAACCCAT 57 [8]
CGGATGTGCGAGCCGTCGACGTCCGC
parC AAGCCGGTACAGCGCCGCATC 57 [8]
GTGGTGCCGTTCAGCAGG
qnrA ATTTCTCACGCCAGGATTTG 55 [19]
GATCGGCAAAGGTTAGGTCA
qnrB GATCGTGAAAGCCAGAAAGG 55 [19]
ACGATGCCTGGTAGTTGTCC
qnrS ACGACATTCGTCAACTGCAA 55 [19]
TAAATTGGCACCCTGTAGGC
aac(6′)-Ib-cr CCCGCTTTCTCGTAGCA 55 This work
TTAGGCATCACTGCGTCTTC
qepA CGTGTTGCTGGAGTTCTTC 59 [3]
CTGCAGGTACTGCGTCATG
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Table 2. MIC determinations in the presence and absence of PAβN, and detection of target gene mutations and plasmid-encoded genes
MIC (μg/ml) QRDR mutation Plasmid-encoded genes
Isolates NALa CIPa GyrA qnr or qepA
Salmonella Enteritidis
16435 128 (8)b 0.125 (0.094) D87Yc –
24097 256 (8) 0.19 (0.19) D87Y –
21380 128 (8) 0.19 (0.19) D87Y –
19505 128 (8) 0.19 (0.19) D87Y –
22679 128 (8) 0.19 (0.19) D87Y –
27341 512 (128) 0.19 (0.19) D87Y –
20055 512 (8) 0.19 (0.19) D87Y –
12345 512 (8) 0.19 (0.19) D87Y –
12333 128 (8) 0.19 (0.125) D87Y –
22601 8 (3) 0.016 (0.016) – qnrB6
29860 256 (8) 0.38 (0.19) S83F –
33910 64 (16) 0.19 (0.125) D87Y –
42565 64 (8) 0.19 (0.094) D87Y –
37453 64 (8) 0.25 (0.19) D87Y –
37141 32 (8) 0.19 (0.19) D87Y –
35397 8 (2) 0.023 (0.016) – –
44819 256 (8) 0.25 (0.125) D87Y –
43735 64 (16) 0.19 (0.125) D87Y –
53908 8 (1.5) 0.012 (0.012) – –
Salmonella Typhimurium –
14630 6 (2) 0.016 (0.012) – –
13920 6 (4) 0.016 (0.012) – –
26986 6 (1.5) 0.023 (0.016) – qnrS1
27562 8 (1.5) 0.016 (0.016) – –
249 8 (1.5) 0.016 (0.012) – qepA
566 12 (4) 0.023 (0.016) – –
21389 6 (1) 0.016 (0.016) – –
13197 8 (2) 0.016 (0.016) – –
12397 8 (3) 0.016 (0.012) – –
7660 6 (4) 0.012 (0.016) – –
40456 6 (1) 0.016 (0.016) – –
26563 12 (6) 0.016 (0.016) – –
27224 8 (1) 0.016 (0.008) – –
30010 12 (8) 0.023 (0.016) – –
(continued)
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All nalidixic acid resistant isolates had a mutation in the
QRDR of the gyrA gene. All substitutions observed were in
codons Ser83 and Asp87: 15 out of the 16 S. Enteritidis resist-
ant isolates carried the substitution D87Y, whereas the remain-
ing isolate carried the substitution S83F. The amino acid
change D87N was detected in the S. Hadar isolate (Table 2).
The association between nalidixic acid resistance and
mutations in the gyrA gene was statistically significant
(Pearson χ2 of 48, on one degree of freedom, P < 0.001). Only
one S. Typhimurium isolate (40456) showed a mutation in the
parC gene, T57S (data not shown), which was associated nei-
ther with decreased susceptibility to ciprofloxacin nor with an
increased MIC of nalidixic acid. Among these isolates, no
mutations were detected in the gyrB gene (data not shown). 
According to the results presented in Table 2, which
shows antimicrobial susceptibility data and mutations in the
QRDR of target genes, the Salmonella isolates were divided
into two groups. The first group comprised the 24 nalidixic
acid susceptible isolates in which no mutation in the target
genes was detected. These isolates had a phenotype highly
susceptible to ciprofloxacin (MICs ≤0.023 μg/ml). When the
MICs were measured in the presence of the efflux pump
inhibitor PAβN, to evaluate the contribution of efflux pump
activity, a 1.5- to 12-fold decrease in the nalidixic acid values
was observed. However, a slight decrease (1.3- to 2-fold) was
detected in 15 of the 24 isolates when we measured the MIC
of ciprofloxacin; the remaining isolates did not show any
change in their MICs. 
The second group comprised those 17 isolates with a
mutation in the gyrA gene. They had a nalidixic acid resist-
ance phenotype, and in all but one isolate, resistance
decreased below the clinical breakpoints of susceptibility
when the MICs were measured in the presence of PAβN. A
4- to 64-fold decrease in the nalidixic acid MIC was detected
in these resistant isolates. This was a considerably greater
reduction than that observed in the nalidixic acid susceptible
isolates, suggesting an increase in efflux pump activity.
Furthermore, the isolates belonging to this group were less
susceptible to ciprofloxacin (MICs of ciprofloxacin:
0.19–0.75 μg/ml). When the MICs of ciprofloxacin were
measured in the presence of PAβN, ten of these nalidixic acid
resistant isolates showed a 1.3- to 2-fold decrease, whereas
no change was detected in any of the other seven isolates. In
all but two isolates (MIC of 0.094 μg/ml), susceptibilities to
ciprofloxacin remained decreased in the presence of PAβN.
There were statistically significant differences at the 5%
level in the MICs of ciprofloxacin depending on the presence
of the efflux pump inhibitor (P = 0.001). In the nalidixic acid
resistant isolates with mutations in the gyrA gene, there were
also statistically significant differences at the 5% level in the
MICs of nalidixic acid that depended on the presence of
PAβN (P > 0.001). The qnr gene was found in three isolates:
a gene with 100% identity with qnrS was detected in one S.
Choleraesuis and one S. Typhimurium, and a gene with 100%
identity with qnrB6 was found in one S. Enteritidis (Table 2).
However, the quinolone susceptibility levels of these isolates
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Table 2. Continued
MIC (μg/ml) QRDR mutation Plasmid-encoded genes
Isolates NALa CIPa GyrA qnr or qepA
43968 6 (1) 0.016 (0.008) – –
39645 8 (0.75) 0.016 (0.008) – –
44615 6 (2) 0.016 (0.012) – –
49758 6 (1.5) 0.016 (0.016) – –
32962 4 (0.5) 0.016 (0.012) – –
Salmonella Choleraesuis
24271 6 (0.5) 0.016 (0.012) – qnrS1
Salmonella Hadar
46324 512 (8) 0.75 (0.38) D87N –
Salmonella Muenchen
49958 12 (1) 0.016 (0.012) – –
a NAL: nalidixic acid; CIP: ciprofloxacin.
b Numbers in parenthesis represent the MICs determined in the presence of PAβN (20 μg/ml).
c D: aspartic acid; Y: tyrosine; S: serine; F: phenylalanine; N: asparagine; –: no mutation found.
19INT. MICROBIOL. Vol.13, 2010
were similar to those of isolates without the qnr genes. A
gene with 100% identity to qepA was found in one S. Ty-
phimurium isolate, although it was not associated with any
phenotype of decreased susceptibility to quinolones, not even
to norfloxacin (MIC of 0.125 μg/ml without PAβN and 0.094
μg/ml with PAβN). The aac(6′)-Ib-cr gene was not found in
this work.
Discussion
Nalidixic acid resistance has increased among Salmonella
clinical isolates over the last few years, whereas cipro-
floxacin resistance remains low [15]. Single mutations in the
gyrA gene have been found to be sufficient for high-level
nalidixic acid resistance in Salmonella [11]. Increased efflux
of the antimicrobial has also been reported to be a common
mechanism and generally represents the first step in the
acquisition of fluoroquinolone resistance [12]. AcrAB/TolC
is the main efflux pump involved in determining intrinsic
levels of resistance in Enterobacteriaceae, according to basal
levels of expression, and confers quinolone resistance when
overexpressed [16]. 
The most important mechanisms producing nalidixic acid
resistance are point mutations in the gyrA gene and increased
efflux contribution. In this study, all of the isolates resistant
to nalidixic acid had a single mutation in gyrA. Furthermore,
the presence of PAβN, an efflux pump inhibitor, rendered all
but one of the nalidixic acid resistant isolates susceptible, and
decreased the MIC of the susceptible isolates to a lesser
extent. However, the MICs of ciprofloxacin decreased only
slightly in the presence of PAβN. These results reinforce the
idea of a constitutive expression of an efflux system, mainly
affecting nalidixic acid extrusion. This efflux system might
be overexpressed in those isolates with a mutation in gyrA,
suggesting a synergistic effect between efflux pumps and
QRDR mutations. However, efflux pump activity could be
less important in decreasing ciprofloxacin susceptibility lev-
els, at least at the low levels of resistance observed in these
isolates. It seems likely that overexpression of the AcrAB-
TolC efflux pump is responsible for this effect, due to the
high prevalence of the efflux pump among clinical isolates
and in vitro mutants of Salmonella [5,6,8], although a con-
comitant overexpression of another efflux pump cannot be
ruled out. Furthermore, this study concurs with previous
research that the T57S substitution detected in ParC is not
associated with a quinolone resistance phenotype since it has
been found in both resistant and susceptible isolates [1].
Concerning the plasmid-encoded determinants, a de-
creased susceptibility to the quinolones nalidixic acid, cipro-
floxacin, or norfloxacin has been reported and ascribed to the
presence of the qnr, aac(6′)-Ib-cr, and qepA genes [18,22,
23], increasing the MICs 16- to 32-fold, 2- to 4-fold, and 32-
to 64-fold, respectively [17]. The highest prevalence of these
genes has been found among Enterobacteriaceae, especially
in Escherichia coli, Enterobacter spp., Klebsiella pneumoni-
ae, and Salmonella spp. The qnr genes have been detected
worldwide, with qnrB being the most prevalent variant.
However, despite their worldwide spread, the prevalence of
the qnr genes is still low in Salmonella spp. (0.2–3%, reach-
ing 9.8% among isolates showing decreased susceptibility to
fluoroquinolones). The aac(6′)-Ib-cr gene may be even more
widespread than qnr, whereas the prevalence of qepA is
apparently low, perhaps reflecting the fact that few studies of
qepA prevalence have been performed [17]. Three out of the
41 isolates (7.3%) tested in this study were positive for the
presence of qnr genes (qnrB6 and qnrS1); only one isolate
(2.4%) showed the presence of qepA. However, aac(6′)-Ib-cr
was not detected. To our knowledge, the qepA gene has not
yet been reported in Salmonella spp. [4,10,13], suggesting
that ours is the first description of the qepA gene and the
qnrB6 variant in Salmonella. Note that the clinical isolates
harboring these plasmid-encoded genes did not show any sig-
nificant change in their MICs when compared with isolates
susceptible to nalidixic acid and negative for the presence of
qnr or qepA.
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